StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.60−0.75 (-1.46%)

Close on Nov 20, 2026

Genmab A/S Other Functional R&D Expense by Year

Other Functional R&D Expense ($M)

Genmab A/S Other Functional R&D Expense: $134M in FY2025, up 21.8% from a year earlier.

Latest, FY2025
134
Period ended Dec 31, 2025
Change on a year earlier
+21.8%
110 in FY2024
History
3 years
Since FY2023
Sources
1
Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.)

Where the FY2025 figure comes from

“|| Other 4 | 134 | 110 | 75 | 22 % | 47 %”

Source: Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Genmab A/S Other Functional R&D Expense ($M), annual FY2023–FY2025 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/rd-func-other

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?